{"analyses":[{"ciLowerLimit":"0.200","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.579","estimateComment":"Hazard ratio (HR) is based on an unstratified Cox proportional hazard regression model with treatment as a factor.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.267","pValueComment":"P-value is from an unstratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.562","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The median and 95% confidence interval (CI) was not estimable as participants were censored.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median and 95% CI was not estimable as the participants were censored.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"Time to AML transformation in HR MDS and CMML participants is defined as time from randomization to documented AML transformation. Participants without documented AML transformation at the time of the analysis are censored at the date of the last assessment. Participants who died before progression to AML are censored at the date of death. Transformation to AML is defined, according to World Health Organization (WHO) classification, as a participant having \\>20% blasts in the blood or marrow and increase of blast count by 50%.","dispersionType":"95% Confidence Interval","groups":[{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG001","title":"Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"ITT Population was defined as all participants who were randomized. Overall number of participants analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","timeFrame":"From date of randomization until transformation to AML (up to approximately 5 years)","title":"Time to AML Transformation in HR MDS or CMML Participants","type":"SECONDARY","unitOfMeasure":"months"}